title: [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
abstract: The relief of insulin resistance is one of the two therapeutic targets of the treatment of type 2 diabetes. Insulin-sensitizers are therefore complemental with other oral diabetic drugs. The treatment of insulin resistance was for a long time limited to dietary and exercise programmes, a biguanide, metformine, and benfluorex, a phenylethylamine derivative; the mechanisms of action of both drugs are now better understood and their indications more precisely targeted. A new therapeutic class, the thiazolidinediones (troglitazone, rosiglitazone, pioglitazone) has recently completed the family of insulin-sensitizing agents. These drugs, which should be soon available in France, act by a different way than metformin, which has been recently identified as the peroxisomes proliferator-activated receptor. The role of antilipolytic agents, which might increase glucose uptake by reducing free fatty acid production and oxidation is under evaluation, as well as the potential benefit of orlistat, an inhibitor of lipid digestion which has been proved effective, in addition to hypocaloric diet, in the management of obese patients.
authors.affiliation: Service de médecine interne B, hôpital civil, hôpitaux universitaires de Strasbourg, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Brogard
authors.forename: N
authors.initials: N
authors.lastname: Neyrolles
authors.forename: E
authors.initials: E
authors.lastname: Andres
authors.forename: J F
authors.initials: JF
authors.lastname: Blicklé
mesh_terms: D000284:Administration, Oral; D002839:Chromans / Q000494:pharmacology / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000178:diet therapy / Q000188:drug therapy* / Q000628:therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015444:Exercise; D005277:Fenfluramine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007333:Insulin Resistance; D007783:Lactones / Q000627:therapeutic use; D008049:Lipase / Q000037:antagonists & inhibitors; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use; D000077403:Orlistat; D020025:Peroxisome Proliferators / Q000494:pharmacology / Q000627:therapeutic use; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use; D045162:Thiazolidinediones; D000077288:Troglitazone
chemical_list: D002839:Chromans; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007783:Lactones; D020025:Peroxisome Proliferators; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D005277:Fenfluramine; C001584:benfluorex; D008687:Metformin; D000077403:Orlistat; D008049:Lipase; D000077288:Troglitazone; D000077205:Pioglitazone